This company listing is no longer active
Marinus Pharmaceuticals (MRNS *) Stock Overview
A pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
MRNS * Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Marinus Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$10.21 |
| 52 Week High | US$124.00 |
| 52 Week Low | US$5.25 |
| Beta | 1.03 |
| 1 Month Change | -8.18% |
| 3 Month Change | 45.86% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | -93.35% |
| Change since IPO | -98.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRNS * | MX Pharmaceuticals | MX Market | |
|---|---|---|---|
| 7D | 0% | 4.8% | 0.8% |
| 1Y | n/a | 7.3% | 24.5% |
Return vs Industry: Insufficient data to determine how MRNS * performed against the MX Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how MRNS * performed against the MX Market.
Price Volatility
| MRNS * volatility | |
|---|---|
| MRNS * Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.2% |
| Market Average Movement | 3.9% |
| 10% most volatile stocks in MX Market | 6.1% |
| 10% least volatile stocks in MX Market | 2.5% |
Stable Share Price: MRNS *'s share price has been volatile over the past 3 months compared to the MX market.
Volatility Over Time: Insufficient data to determine MRNS *'s volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 166 | Scott Braunstein | marinuspharma.com |
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The company’s ZTALMY product candidate acts at synaptic and extrasynaptic GABAA receptors, a target for its anti-seizure, antidepressant, and anxiolytic potential.
Marinus Pharmaceuticals, Inc. Fundamentals Summary
| MRNS * fundamental statistics | |
|---|---|
| Market cap | Mex$622.67m |
| Earnings (TTM) | -Mex$2.88b |
| Revenue (TTM) | Mex$646.11m |
Is MRNS * overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRNS * income statement (TTM) | |
|---|---|
| Revenue | US$31.47m |
| Cost of Revenue | US$102.78m |
| Gross Profit | -US$71.31m |
| Other Expenses | US$69.18m |
| Earnings | -US$140.49m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.55 |
| Gross Margin | -226.64% |
| Net Profit Margin | -446.49% |
| Debt/Equity Ratio | -141.4% |
How did MRNS * perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/09 23:49 |
| End of Day Share Price | 2025/01/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marinus Pharmaceuticals, Inc. is covered by 7 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| François Brisebois | Craig-Hallum Capital Group LLC |
| Douglas Tsao | H.C. Wainwright & Co. |
| Kimberly Lee | Janney Montgomery Scott LLC |